Sex differences in BAG across the AD continuum were largely explained by APOE {epsilon}4-related acceleration rather than by an independent effect of sex alone, which suggests that females may be more vulnerable to APOE {epsilon}4-associated structural brain aging over time.
Abstract
INTRODUCTION: Brain age gap (BAG) is the difference between a person's chronological age and the age predicted from the structural appearance of their brain on MRI. A higher BAG indicates an older-appearing brain and provides a global marker of structural brain aging across the Alzheimer's disease continuum. Prior studies suggest that females may show greater Alzheimer's disease-related pathology or faster late-stage neurodegeneration than males. We tested whether sex was associated with baseline BAG or longitudinal BAG change after accounting for APOE {epsilon}4 genetic risk, amyloid positivity, cognitive severity, and disease stage.
Methods
We developed a domain-adaptive deep learning model to estimate BAG from T1-weighted MRIs, training it on 26,512 neurologically healthy UK Biobank data and fine-tuning it on 2,974 amyloid-negative cognitively normal samples from Mayo Clinic Study of Aging and OASIS-3 cohorts. We applied the model to ADNI and used hierarchical mixed-effects models to test whether sex was associated with BAG trajectories after adjusting for Alzheimer's disease risk factors.
Results
After adjustment for Alzheimer's disease risk factors, there was no baseline sex differences in BAG. Longitudinally, females showed greater BAG acceleration than males, but this effect was moderated by APOE {epsilon}4 status. APOE {epsilon}4 accelerated brain aging in a dose-dependent manner, independent of amyloid burden.
Discussion
Sex differences in BAG across the AD continuum were largely explained by APOE {epsilon}4-related acceleration rather than by an independent effect of sex alone. These findings suggest that females may be more vulnerable to APOE {epsilon}4-associated structural brain aging over time.
BAG is a reliable non-invasive marker of structural brain health sensitive to AD pathology and to modifiable AD risk and supports its relevance for early risk stratification and prevention-oriented research.
E. Kuhn, G. Antopoulos, L. Kleineidam et al.· medRxiv· 0 citations
The emerging findings highlight the importance of jointly considering biological sex and APOE ε4 status to improve the characterization of Alzheimer’s disease heterogeneity and support precision medicine approaches.
Wanessa Michelin, Joana O. Pinto, B. Peixoto· Life· 0 citations
The early detection of individuals with Mild Cognitive Impairment (MCI) who are at high risk of developing Alzheimer’s Disease (AD) is important for proper clinical intervention and disease management. Studies show that there is a strong link between brain age, which is estimated from brain scan data, and actual chrono...
B. Stanley, K. Sindhubala, J. S. Shemona et al.· International Conference on...· 0 citations
A specific brain aging phenotype is suggested as a potential intermediate pathway linking tau-related pathology to cognition prior to clinical impairment in cognitively unimpaired adults.
Nicholas Riccardi, Ansley Martin, Dariusz Pytel et al.· npj Dementia· 1 citation
In cognitively unimpaired older adults, elevated blood p-tau217 was linked to faster shrinkage in AD-specific brain regions, whereas NfL and GFAP were associated with more widespread atrophy, with NfL also associated with accelerated WMH accumulation.
Martina Valletta, D. L. Vetrano, E. J. Laukka et al.· Annals of Neurology· 0 citations
It is demonstrated that brain-PAD is a clinically meaningful, transdiagnostic biomarker of neurodegeneration that complements conventional volumetric measures like the BPF.
Lonneke Bos, D. V. van Nederpelt, J. Cole et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.